These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36642497)

  • 1. Everyone Wins: Vaccine Lotteries Can Cost-Effectively Increase COVID-19 Booster Vaccination Rates.
    McLaren ZM
    Am J Epidemiol; 2023 Apr; 192(4):510-513. PubMed ID: 36642497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the effectiveness of COVID-19 vaccine lotteries: A cross-state synthetic control methods approach.
    Fuller S; Kazemian S; Algara C; Simmons DJ
    PLoS One; 2022; 17(9):e0274374. PubMed ID: 36170293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the Impact of Vaccine Lotteries on COVID-19 Vaccination Rates in the United States in 2021.
    Sload J; Bechtolsheim B; Gifford D
    Am J Public Health; 2022 Aug; 112(8):1130-1133. PubMed ID: 35737921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are vaccine lotteries worth the money?
    Robertson C; Schaefer KA; Scheitrum D
    Econ Lett; 2021 Dec; 209():110097. PubMed ID: 35153345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
    Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
    Elife; 2023 Jan; 12():. PubMed ID: 36692910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events following third dose of mRNA COVID-19 vaccination among nursing home residents who received the primary series.
    Bardenheier BH; White EM; Blackman C; Gravenstein S; Gutman R; Sarkar IN; Feifer RA; McConeghy K; Nanda A; Duprey M; Mor V
    J Am Geriatr Soc; 2022 Jun; 70(6):1642-1647. PubMed ID: 35460263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different Interventions for COVID-19 Primary and Booster Vaccination? Effects of Psychological Factors and Health Policies on Vaccine Uptake.
    Sprengholz P; Henkel L; Böhm R; Betsch C
    Med Decis Making; 2023 Feb; 43(2):239-251. PubMed ID: 36404766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conditional cash lotteries increase COVID-19 vaccination rates.
    Barber A; West J
    J Health Econ; 2022 Jan; 81():102578. PubMed ID: 34986437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of State Vaccine Incentive Lottery Programs and Uptake of COVID-19 Vaccinations in the United States.
    Acharya B; Dhakal C
    JAMA Netw Open; 2021 Dec; 4(12):e2138238. PubMed ID: 34882179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global diversity of policy, coverage, and demand of COVID-19 vaccines: a descriptive study.
    Chen Z; Zheng W; Wu Q; Chen X; Peng C; Tian Y; Sun R; Dong J; Wang M; Zhou X; Zhao Z; Zhong G; Yan X; Liu N; Hao F; Zhao S; Zhuang T; Yang J; Azman AS; Yu H
    BMC Med; 2022 Apr; 20(1):130. PubMed ID: 35369871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A citywide experiment testing the impact of geographically targeted, high-pay-off vaccine lotteries.
    Milkman KL; Gandhi L; Ellis SF; Graci HN; Gromet DM; Mobarak RS; Buttenheim AM; Duckworth AL; Pope D; Stanford A; Thaler R; Volpp KG
    Nat Hum Behav; 2022 Nov; 6(11):1515-1524. PubMed ID: 36050387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between statewide financial incentive programs and COVID-19 vaccination rates.
    Thirumurthy H; Milkman KL; Volpp KG; Buttenheim AM; Pope DG
    PLoS One; 2022; 17(3):e0263425. PubMed ID: 35353815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interventions to increase COVID-19 vaccine uptake: a scoping review.
    Andreas M; Iannizzi C; Bohndorf E; Monsef I; Piechotta V; Meerpohl JJ; Skoetz N
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015270. PubMed ID: 35920693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acceptance of COVID-19 Vaccine Booster Doses Using the Health Belief Model: A Cross-Sectional Study in Low-Middle- and High-Income Countries of the East Mediterranean Region.
    Ghazy RM; Abdou MS; Awaidy S; Sallam M; Elbarazi I; Youssef N; Fiidow OA; Mehdad S; Hussein MF; Adam MF; Abdullah FSA; Rebai WK; Raad EB; Hussein M; Shehata SF; Ismail II; Salam AA; Samhouri D
    Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F;
    Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inequities in COVID-19 vaccine and booster coverage across Massachusetts ZIP codes after the emergence of Omicron: A population-based cross-sectional study.
    Bor J; Assoumou SA; Lane K; Diaz Y; Ojikutu BO; Raifman J; Levy JI
    PLoS Med; 2023 Jan; 20(1):e1004167. PubMed ID: 36719864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceptance of the COVID-19 vaccine booster dose and associated factors among the elderly in China based on the health belief model (HBM): A national cross-sectional study.
    Qin C; Yan W; Du M; Liu Q; Tao L; Liu M; Liu J
    Front Public Health; 2022; 10():986916. PubMed ID: 36589991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.
    Prasad N; Derado G; Nanduri SA; Reses HE; Dubendris H; Wong E; Soe MM; Li Q; Dollard P; Bagchi S; Edwards J; Shang N; Budnitz D; Bell J; Verani JR; Benin A; Link-Gelles R; Jernigan J; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2022 May; 71(18):633-637. PubMed ID: 35511708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jordanians' willingness to receive heterologous prime-boost COVID-19 vaccination and vaccine boosters.
    Rababa'h AM; Abedalqader NN; Ababneh M
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7516-7525. PubMed ID: 34919254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.